Search results for "BINOL"

showing 10 items of 41 documents

Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation an…

2020

Background/Objective Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT). This necessitates the development of new complementary drugs, e.g., cannabinoid receptors (CB1 and CB2) agonists including tetrahydrocannabinol (THC) and cannabidiol (CBD). The combined use of THC and CBD confers greater benefits, as CBD enhances the effects of THC and reduces its psychotropic activity. We assessed the relationship between the expression levels of CB1 and CB2 to the clinical features of a cohort of patients with NSCLC, and the effect of THC and CBD (individually and in combination) on prolifer…

0301 basic medicineMaleCannabinoid receptorLung NeoplasmsPulmonologymedicine.medical_treatmentGene ExpressionBiochemistryLung and Intrathoracic TumorsReceptor Cannabinoid CB20302 clinical medicineContractile ProteinsReceptor Cannabinoid CB1Epidermal growth factorCarcinoma Non-Small-Cell LungMedicine and Health SciencesCannabidiolDronabinolAged 80 and overMultidisciplinaryChemistryQRDrugsMiddle AgedCancer Cell MigrationCell MotilityOncologyCell Processes030220 oncology & carcinogenesisMedicinelipids (amino acids peptides and proteins)Femalemedicine.drugResearch ArticleAdultEpithelial-Mesenchymal TransitionScienceChronic Obstructive Pulmonary DiseaseCell Migration03 medical and health sciencesCell Line Tumormental disordersmedicineGeneticsHumansEpithelial–mesenchymal transitionTetrahydrocannabinolCell ProliferationAgedA549 cellPharmacologyCannabinoid Receptor AgonistsPsychotropic DrugsCell growthCannabinoidsorganic chemicalsCancers and NeoplasmsBiology and Life SciencesProteinsCell Biologydigestive system diseasesActinsrespiratory tract diseasesNon-Small Cell Lung CancerCytoskeletal Proteins030104 developmental biologyA549 CellsCancer researchCannabinoidCannabidiolDevelopmental BiologyPLoS ONE
researchProduct

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

2013

UNLABELLED: Cannabis use is associated with an earlier age of onset of psychosis (AOP). However, the reasons for this remain debated. METHODS: We applied a Cox proportional hazards model to 410 first-episode psychosis patients to investigate the association between gender, patterns of cannabis use, and AOP. RESULTS: Patients with a history of cannabis use presented with their first episode of psychosis at a younger age (mean years = 28.2, SD = 8.0; median years = 27.1) than those who never used cannabis (mean years = 31.4, SD = 9.9; median years = 30.0; hazard ratio [HR] = 1.42; 95% CI: 1.16-1.74; P < .001). This association remained significant after controlling for gender (HR = 1.39; 95% …

AdultAffective Disorders PsychoticMaleRiskage of onset cannabis drug use gender high-potency cannabis psychotic disorders survival plotsPsychosisPediatricsmedicine.medical_specialtySex FactorsDelta-9-tetrahydrocannabinolSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.medicineHumansAge of OnsetPsychiatrySettore MED/25 - PsichiatriaCannabisFirst episodebiologyProportional hazards modelHazard ratioRegular Articlemedicine.diseasebiology.organism_classificationPsychiatry and Mental healthPsychotic DisordersSchizophreniaFemaleCannabisAge of onsetPsychologySchizophrenia bulletin
researchProduct

Concentrations of  9-Tetrahydrocannabinol and 11-Nor-9-Carboxytetrahydrocannabinol in Blood and Urine After Passive Exposure to Cannabis Smoke in a C…

2010

Cannabinoid concentrations in blood and urine after passive exposure to cannabis smoke under real-life conditions were investigated in this study. Eight healthy volunteers were exposed to cannabis smoke for 3 h in a well-attended coffee shop in Maastricht, Netherlands. An initial blood and urine sample was taken from each volunteer before exposure. Blood samples were taken 1.5, 3.5, 6, and 14 h after start of initial exposure, and urine samples were taken after 3.5, 6, 14, 36, 60, and 84 h. The samples were subjected to immunoassay screening for cannabinoids and analyzed using gas chromatography-mass spectrometry (GC-MS) for Delta(9)-tetrahydrocannabinol (THC), 11-nor-hydroxy-Delta(9)-tetra…

AdultMaleTime FactorsHealth Toxicology and Mutagenesismedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayUrineToxicologyGas Chromatography-Mass SpectrometryAnalytical ChemistryPharmacokineticsLimit of DetectionSmokemental disordersmedicineHumansEnvironmental ChemistryDronabinolSolid phase extractionVolunteerCannabisNetherlandsInhalation exposureInhalation ExposureChemical Health and SafetyChromatographymedicine.diagnostic_testChemistryorganic chemicalsReproducibility of ResultsMiddle AgedAir Pollution IndoorImmunoassayFemaleCannabinoidGas chromatography–mass spectrometryJournal of Analytical Toxicology
researchProduct

An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples.

2004

Preanalytical stability of a drug and its major metabolites is an important consideration in pharmacokinetic studies or whenever the analyte pattern is used to estimate drug habits. Firstly, the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH, THCCOOglu) in authentic urine samples was investigated. Random urine samples of cannabis users (n = 38) were stored at -20, 4, and 20 degrees C up to 15 days and up to 5 days at 40 degrees C, and alterations of the analyte pattern during storage were followed by liquid chromatography-tandem mass spectrometry. Secondly, the influence of pH (range 5.0-8.0) on the stability of the analytes was studied us…

AnalyteSubstance-Related DisordersHealth Toxicology and MutagenesisCarboxylic acidMetaboliteUrineToxicologyHigh-performance liquid chromatographyMass SpectrometryAnalytical Chemistrychemistry.chemical_compoundGlucuronidesPharmacokineticsDrug StabilityEnvironmental ChemistryHumansDronabinolDiagnostic Errorschemistry.chemical_classificationChemical Health and SafetyChromatographyForensic MedicineHydrogen-Ion ConcentrationSubstance Abuse DetectionchemistryΔ9-tetrahydrocannabinolGlucuronideArtifactsJournal of analytical toxicology
researchProduct

Cannabis and the Mesolimbic System

2016

Abstract Cannabis sativa (hemp) is a flowering annual plant whose phytochemical by-products, hashish and marihuana, are the most widely produced and most frequently used illicit drugs in Europe. Δ 9 -Tetrahydrocannabinol is the primary psychoactive constituent, responsible, in a dose-related manner, for euphoria, cognitive effects, and psychotic symptoms, as well as the addictive potential of smoked cannabis due to its interference with the mesolimbic dopaminergic system. Cannabis as well as endocannabinoids acts mainly at the presynaptic levels in several brain regions, including the nucleus accumbens and ventral tegmental area, where it modulates synaptic activity. Through the modulation …

CB1 receptorCannabinoid receptorDopaminergic transmissionmedicine.medical_treatmentHashishNucleus accumbensPharmacologymedicineCannabiDependenceTetrahydrocannabinolMesolimbic systembiologyMedicine (all)food and beveragesbiology.organism_classificationEndocannabinoid systemVentral tegmental areamedicine.anatomical_structure9-THCWithdrawalCannabinoidCannabisPsychologyNeurosciencemedicine.drug
researchProduct

Extensive phytocannabinoid profiles of seized cannabis and cannabis-based medicines – Identification of potential distinguishing markers

2021

As the frequency of cannabis-based therapy increases, the ability to distinguish intake of cannabis-based medicines from recreational cannabis use becomes desirable. Minor cannabinoids have been suggested to indicate recreational cannabis use in biological matrices but are unreliable when presumably also present in directly plantderived medicines. Thus, for therapeutics such as medical cannabis, Sativex® and Dronabinol, a more thorough investigation of cannabinoid profiles is required to identify possible distinguishing markers. In this study, 16 phytocannabinoids were quantified in samples of seized and medical cannabis, Sativex® and Dronabinol from two different manufacturers, using a val…

Cannabigerolmedicine.medical_treatmentMedical MarijuanaTetrahydrocannabivarinMass SpectrometryCannabicyclolPathology and Forensic MedicineCannabichromenechemistry.chemical_compoundmedicineCannabidiolHumansDronabinolPrincipal Component AnalysisbiologyTraditional medicineCannabinoidsbusiness.industrybiology.organism_classificationDrug CombinationschemistryCannabinolCannabinoidCannabisDronabinolbusinessLawChromatography Liquidmedicine.drugForensic Science International
researchProduct

Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples

2021

Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medicines were investigated, in order to identify potential distinguishing markers. Serum samples after use of Sativex®, Dronabinol or medical cannabis were collected and analyzed for 18 different cannabinoids, using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Analytes included delta-9-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, …

Cannabigerolprincipal component analysisEndocrinology Diabetes and MetabolismTetrahydrocannabivarin01 natural sciencesBiochemistryMicrobiologyArticleCannabicyclol03 medical and health sciencesCannabichromenechemistry.chemical_compoundcannabinoids0302 clinical medicinemedicineserum concentrations030216 legal & forensic medicineDronabinolLC-MS/MSMolecular BiologybiologyTraditional medicinebusiness.industry010401 analytical chemistrymedical cannabisbiology.organism_classificationSativexQR1-5020104 chemical scienceschemistryCannabinolCannabisDronabinolbusinessCannabidiolmedicine.drugMetabolites
researchProduct

Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis.

2011

Abstract Cannabinoid CB1 receptors (CB1Rs) regulate the neurodegenerative damage of experimental autoimmune encephalomyelitis (EAE) and of multiple sclerosis (MS). The mechanism by which CB1R stimulation exerts protective effects is still unclear. Here we show that pharmacological activation of CB1Rs dampens the tumor necrosis factor α (TNFα)-mediated potentiation of striatal spontaneous glutamate-mediated excitatory postsynaptic currents (EPSCs), which is believed to cogently contribute to the inflammation-induced neurodegenerative damage observed in EAE mice. Furthermore, mice lacking CB1Rs showed a more severe clinical course and, in parallel, exacerbated alterations of sEPSC duration af…

Cannabinoid receptorEncephalomyelitis Autoimmune ExperimentalPolyunsaturated Alkamidesmedicine.medical_treatmentImmunologyExcitotoxicityGlutamic AcidArachidonic AcidsPharmacologyBiologymedicine.disease_causeReceptors N-Methyl-D-AspartateReceptors Tumor Necrosis FactorAmidohydrolasesEtanerceptBehavioral Neurosciencechemistry.chemical_compoundMiceReceptor Cannabinoid CB1Fatty acid amide hydrolaseCannabinoid Receptor ModulatorsmedicineAnimalsDronabinolReceptors AMPA6-Cyano-7-nitroquinoxaline-23-dioneMice KnockoutNeuronsEndocrine and Autonomic SystemsTumor Necrosis Factor-alphaNeurodegenerationExperimental autoimmune encephalomyelitisExcitatory Postsynaptic PotentialsAnandamidemedicine.diseaseEndocannabinoid systemCorpus StriatumMice Inbred C57BLchemistryImmunoglobulin GImmunologyNerve DegenerationSettore MED/26 - NeurologiaFemaleCannabinoidDizocilpine MaleateEndocannabinoidsBrain, behavior, and immunity
researchProduct

Follow up: palmitic acid ester of tetrahydrocannabinol (THC) and palmitic acid diester of 11-hydroxy-THC – unsuccessful search for additional THC met…

2020

Abstract Objectives In a previous investigation we searched for the occurrence of palmitic acid ester compounds of delta9-tetrahydrocannabinol (THC) and its primary metabolite 11-hydroxy-delta9-THC (11-OH-THC) in human body fluids and tissues (THC palmitic acid monoester [THC-Pal] and 11-OH-THC palmitic acid diester [11-OH-THC-DiPal]). As those esters could not be detected in various human body fluids (e.g. blood) or tissues (e.g. adipose tissue) we extended the investigation analyzing adipose tissue samples of mice previously given synthetic THC or a cannabis extract. Methods In total, 48 adipose tissue samples previously tested positive for THC by means of a liquid chromatographic triple …

ChromatographyChemistry11-Hydroxy-THCPalmitic AcidPrimary metaboliteAdipose tissueEstersMass spectrometricGas Chromatography-Mass SpectrometryTriple quadrupole mass spectrometerPalmitic acidMicechemistry.chemical_compoundmedicineAnimalsHumansPharmacology (medical)DronabinolGeneral Pharmacology Toxicology and PharmaceuticsTetrahydrocannabinolChromatography Liquidmedicine.drugDrug Metabolism and Personalized Therapy
researchProduct

Simultaneous quantification of 18 different phytocannabinoids in serum using a highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS…

2021

Abstract The potential therapeutic effects of various phytocannabinoids and the availability of multiple cannabis-based medicines make it desirable to have an analytical method that simultaneously quantifies a wide range of cannabinoids in blood, beyond delta-9-tetrahydrocannabinol and its metabolites. A liquid chromatography tandem mass spectrometry (LC-MS/MS) method for quantification of 18 phytocannabinoids and cannabinoid metabolites in serum was developed and validated. The method enables simultaneous detection of delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabicyclol, tetrahydrocannabivarin and cannabidivarin and their acidic precursors tet…

Detection limitChromatographyCannabigerol010401 analytical chemistryClinical BiochemistryCell BiologyGeneral MedicineTetrahydrocannabivarin030226 pharmacology & pharmacy01 natural sciencesBiochemistryCannabicyclol0104 chemical sciencesAnalytical Chemistry03 medical and health scienceschemistry.chemical_compoundCannabichromene0302 clinical medicinechemistryLiquid chromatography–mass spectrometrymedicineCannabinolSolid phase extractionmedicine.drugJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct